Aspen Pharmacare
Eikance Atropine
Australia's first TGA-approved atropine eye drop for myopia control, commercially manufactured at a consistent, well-studied 0.01% concentration.
Australia's first TGA-approved atropine eye drop for myopia control, commercially manufactured at a consistent, well-studied 0.01% concentration.
For years, Australian optometrists prescribing low-dose atropine for myopia control relied on compounding pharmacies to prepare it, since no commercially manufactured, TGA-approved product existed locally. Eikance, made by Aspen Pharmacare, changed that, becoming the first atropine eye drop specifically approved by the TGA in Australia for slowing myopia progression in children.
It's manufactured at a fixed 0.01% concentration, the same dose extensively studied in major international trials, produced under standardised commercial quality control rather than pharmacy-by-pharmacy compounding. See our Atropine Eye Drops page for how low-dose atropine works more broadly.
Eikance's 0.01% concentration is the same dose used in some of the largest atropine myopia control trials, including arms of the LAMP study, giving prescribers a well-characterised evidence base to draw on. At this lower end of the low-dose range, the myopia control effect is generally milder than higher concentrations, but side effects such as light sensitivity tend to be correspondingly mild too.
That balance makes Eikance a sensible starting point for many children, with the option to step up to a higher, compounded concentration later if progression continues at a faster rate than we'd like.
Being TGA-approved means Eikance has gone through Australia's formal regulatory assessment for quality, safety and manufacturing consistency specifically for this indication, an assurance that compounded formulations, while clinically useful and commonly prescribed, don't carry in the same regulatory form.
Eikance suits families who want a TGA-approved, commercially manufactured atropine option at a well-studied starting concentration, and children for whom 0.01% is an appropriate starting dose based on their progression rate and our optometrist's assessment.
It's one option within our broader atropine treatment category, itself one of our five treatment options. If a different concentration is needed, our compounded atropine page explains that alternative.
Book a comprehensive myopia assessment and we'll talk through Eikance and how it compares with our other treatment options for your child specifically.